MT-3724 for Treatment of Relapsed/Refractory DLBCL

Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with relapsed or refractory DLBCL.

  • Clinical Trial Information

    Trial Contact: Walton, Sherri; Manchola-Orozco, Carolina

    Trial Phone: 321.841.1907 ; 321.841.7293

  • IRB No: 19.201.06

    Protocol Abbrev: MT-3724_NHL_001

    Principal Investigator: Jose E. Sarriera, MD

    Phase: Drug: Phase II

    Age Group: Adult

    Secondary Protocol No: MT-3724

    Treatment: MT-3724 50 μg/kg/dose/day with a maximum of 6000 μg/dose/day

    Therapies Involved: Oncology: 3rd line/Refractory ID: NCT02361346

  • Objective

    Determine the efficacy of MT-3724 as monotherapy in subjects with relapsed or refractory DLBCL based on the overall response rate (ORR)

  • Key Eligibility

    Subjects with histologically confirmed, relapsed or refractory DLBCL who have received at least 2 standard of care systemic NHL treatment regimens will be enrolled. Subjects must have at least one histologically confirmed diagnosis of DLBCL determined by excisional or core biopsy